SCHEMBL11631034

SCHEMBL11631034

CC(=O)Oc1ccccc1/C=C/c1ccccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.57
▸ NPC1 O15118 7/20 0.57
▸ RAB9A P51151 7/20 0.57
▸ MAPT P10636 6/20 0.57
▸ MAPK1 P28482 4/20 0.57
▸ GAA P10253 2/20 0.57
▸ MEN1 O00255 8/20 0.51
▸ KMT2A Q03164 8/20 0.51
▸ HSP90AA1 P07900 1/20 0.51
▸ ATM Q13315 1/20 0.48
▸ ALDH1A1 P00352 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ TP53 P04637 1/20 0.46
▸ NFKB1 P19838 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11631039 1.00 KDM4E (0.57) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL16915443 0.86 KMT2A (0.52) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL16915441 0.86 KMT2A (0.52) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL16915450 0.86 KMT2A (0.47) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL16915451 0.86 KMT2A (0.47) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL1603612 0.85 MEN1 (0.60) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL4715311 0.81 MEN1 (0.52) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL4715307 0.81 MEN1 (0.52) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL19076160 0.79 NPC1 (0.74) KDM4ENPC1RAB9AMAPTMAPK1
SCHEMBL15330637 0.79 CDK4 (0.52) KDM4ENPC1RAB9AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975860-B2 Anti-angiogenic compounds UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2018-05-22 — — US disclosed
US-9975860-B2 Anti-angiogenic compounds UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2018-05-22 — — US disclosed
US-9975860-B2 Anti-angiogenic compounds UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2018-05-22 — — US disclosed
EP-3094625-A1 ANTI-ANGIOGENIC COMPOUNDS University College Dublin National University Of Ireland, Dublin (IE) 2016-11-23 — — EP disclosed
US-20160326122-A1 Anti-Angiogenic Compounds UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2016-11-10 — — US disclosed
US-20160326122-A1 Anti-Angiogenic Compounds UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2016-11-10 — — US disclosed
US-20160326122-A1 Anti-Angiogenic Compounds UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2016-11-10 — — US disclosed
WO-2015107122-A1 ANTI-ANGIOGENIC COMPOUNDS UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2015-07-23 — — WO disclosed
US-4130650-A 1-METHYL- OR DIMETHYL-AMINOETHOXY, 2-PYRIDYLVINYL-BENZENE BOEHRINGER INGELHEIM GMBH (DE) 1978-12-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326122-A1 Anti-Angiogenic Compounds VEGFA, FLT4, FLT1 KDM4E 4170/4885NPC1 3155/4885RAB9A 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback